Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MIRM Mirum Pharmaceuticals, Inc.

未开盘 01-12 16:00:00 EST

89.50

+2.93

+3.38%

盘后90.00

+0.50+0.56%

19:36 EST

最高90.08	最低82.00	成交量122.95万
今开85.62	昨收86.57	日振幅9.33%
总市值46.26亿	流通市值35.79亿	总股本5,168万
成交额1.08亿	换手率3.07%	流通股本3,999万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MIRM","market":"US","secType":"STK","nameCN":"Mirum Pharmaceuticals, Inc.","latestPrice":89.5,"timestamp":1768251600000,"preClose":86.57,"halted":0,"volume":1229499,"hourTrading":{"tag":"盘后","latestPrice":90,"preClose":89.5,"latestTime":"19:36 EST","volume":54531,"amount":4881205.06,"timestamp":1768264582041},"delay":0,"floatShares":39985740,"shares":51683837,"eps":-0.83931,"marketStatus":"未开盘","change":2.93,"latestTime":"01-12 16:00:00 EST","open":85.62,"high":90.08,"low":82,"amount":108341982.628695,"amplitude":0.093335,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.83931,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768294800000},"marketStatusCode":0,"adr":0,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":86.57,"preHourTrading":{"tag":"盘前","latestPrice":84.7,"preClose":86.57,"latestTime":"09:19 EST","volume":58066,"amount":5026621.19675,"timestamp":1768227589278},"postHourTrading":{"tag":"盘后","latestPrice":90,"preClose":89.5,"latestTime":"19:36 EST","volume":54531,"amount":4881205.06,"timestamp":1768264582041},"volumeRatio":1.474905,"impliedVol":0.2586,"impliedVolPercentile":0.0558},"requestUrl":"/m/hq/s/MIRM","defaultTab":"news","newsList":[{"id":"1185803639","title":"Mirum制药公司2025年初步净产品销售额约5.2亿美元 超预期指引上限","url":"https://stock-news.laohu8.com/highlight/detail?id=1185803639","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185803639?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:33","pubTimestamp":1768224780,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 近日公布的2025年初步业绩数据显示，其净产品销售额达到约5.2亿美元，这一数字显著超越了公司此前设定的业绩指引上限。\n这一亮眼成绩凸显了公司核心产品的市场竞争力与商业化进展。销售额的超预期表现，不仅反映了患者需求的持续增长，也印证了公司销售策略的有效执行。在医药行业面临多重挑战的背景下，Mirum能够实现如此强劲的销售增长，为其未来的发展奠定了坚实的基础。\n市场分析人士认为，这一积极的初步数据可能会增强投资者信心，并对公司未来的股价表现产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1116304908","title":"Mirum制药公司：伏利昔巴特治疗原发性硬化性胆管炎Vistas研究顶线数据预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1116304908","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116304908?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:32","pubTimestamp":1768224761,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.宣布，其针对原发性硬化性胆管炎（PSC）开发的伏利昔巴特（volixibat）Vistas研究，预计将于2026年第二季度获得顶线数据。该研究旨在评估伏利昔巴特治疗这一慢性胆汁淤积性肝病的疗效与安全性。\n此次数据公布将成为评估该疗法潜力的关键节点，备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1137824651","title":"Mirum Pharma首席执行官表示，Brelovitug的加入将使其罕见疾病组合的收入潜力超过40亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137824651","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137824651?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:43","pubTimestamp":1765201436,"startTime":"0","endTime":"0","summary":"Mirum Pharma首席执行官表示，Brelovitug的加入将使其罕见疾病组合的收入潜力超过40亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1114154154","title":"Mirum Pharmaceuticals拟以2.5亿美元现金、3.7亿美元公司普通股以及最多2亿美元的销售里程碑付款收购Bluejay","url":"https://stock-news.laohu8.com/highlight/detail?id=1114154154","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114154154?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:06","pubTimestamp":1765199171,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals拟以2.5亿美元现金、3.7亿美元公司普通股以及最多2亿美元的销售里程碑付款收购Bluejay。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1168670915","title":"Mirum Pharmaceuticals：与医疗投资者联络组达成私募协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1168670915","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168670915?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:03","pubTimestamp":1765199025,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals：与医疗投资者联络组达成私募协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1133302222","title":"Mirum Pharmaceuticals达成收购Bluejay Therapeutics的最终协议，扩展在罕见疾病领域的全球领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1133302222","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133302222?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:03","pubTimestamp":1765198995,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals达成收购Bluejay Therapeutics的最终协议，扩展在罕见疾病领域的全球领导地位","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1194128623","title":"Mirum Pharmaceuticals：预计私人融资将与收购同时完成，并为公司带来约2亿美元的总收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1194128623","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194128623?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:01","pubTimestamp":1765198897,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals：预计私人融资将与收购同时完成，并为公司带来约2亿美元的总收益","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1157964241","title":"Mirum Pharmaceuticals：Azure三期项目正在招募患者，预计在2026年下半年获得主要数据，BLA申请及计划于2027年上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1157964241","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157964241?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:01","pubTimestamp":1765198895,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals：Azure三期项目正在招募患者，预计在2026年下半年获得主要数据，BLA申请及计划于2027年上市","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1145122409","title":"Mirum Pharmaceuticals宣布在Bloom第二阶段临床研究中招募首位患者，评估Mrm-3379在脆性X综合症中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1145122409","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145122409?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:11","pubTimestamp":1764594695,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals宣布在Bloom第二阶段临床研究中招募首位患者，评估Mrm-3379在脆性X综合症中的应用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"2558669168","title":"Mirum Pharmaceuticals, Inc.盘中异动 股价大涨5.05%报63.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558669168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558669168?lang=zh_cn&edition=full","pubTime":"2025-08-11 22:07","pubTimestamp":1754921250,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日22时07分，Mirum Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.05%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。其相关个股中，Equillium, Inc.、Entero Therapeutics Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Entero Therapeutics Inc.、Equillium, Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为4001.34%、324.77%、100.30%，振幅较大的相关个股有Entero Therapeutics Inc.、Equillium, Inc.、Jyong Biotech Ltd.，振幅分别为74.27%、70.68%、44.39%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司， 专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508112207309740f1c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508112207309740f1c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1176048338","title":"异动解读 | 业绩超预期并上调全年指引，Mirum Pharmaceuticals盘中大涨8.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176048338","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176048338?lang=zh_cn&edition=full","pubTime":"2025-08-07 22:00","pubTimestamp":1754575252,"startTime":"0","endTime":"0","summary":"周四盘中，生物制药公司Mirum Pharmaceuticals, Inc.股价大涨8.72%，引起市场广泛关注。这一显著涨幅主要受益于公司发布的强劲第二季度财务业绩报告以及上调的全年收入指引。根据公司公布的2025年第二季度财报，Mirum总营收达到1.28亿美元，表现优异。基于良好的商业表现，Mirum将2025年全年营收指引上调至4.9亿至5.1亿美元，进一步提振了投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"gpt_icon":1},{"id":"2557628569","title":"Mirum Pharmaceuticals, Inc.盘中异动 早盘大幅拉升5.99%报56.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557628569","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557628569?lang=zh_cn&edition=full","pubTime":"2025-08-07 21:31","pubTimestamp":1754573472,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日21时31分，Mirum Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.99%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Palisade Bio, Inc.、Niagen Bioscience, Inc.、Sarepta Therapeutics, Inc.涨幅较大，Palisade Bio, Inc.、Processa Pharmaceuticals, Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为338.37%、61.84%、20.51%，振幅较大的相关个股有Lantern Pharma Inc.、Palisade Bio, Inc.、Xeris制药，振幅分别为101.17%、14.00%、12.75%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司， 专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807213112a47b244b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807213112a47b244b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1156750369","title":"异动解读 | Mirum Pharmaceuticals盘前大涨7.70%，Q2业绩超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1156750369","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156750369?lang=zh_cn&edition=full","pubTime":"2025-08-07 20:41","pubTimestamp":1754570516,"startTime":"0","endTime":"0","summary":"生物制药公司Mirum Pharmaceuticals, Inc.今日盘前大涨7.70%，主要受益于公司发布的强劲第二季度财报以及上调的全年业绩指引。根据公司公告，Mirum第二季度总营收达到1.28亿美元，表现优异。鉴于良好的商业表现，Mirum将2025年全年营收指引上调至4.9亿至5.1亿美元，进一步提振了投资者信心。除了财务业绩亮眼外，Mirum的药物研发管线也取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"gpt_icon":1},{"id":"1195849493","title":"异动解读 | Mirum Pharmaceuticals盘前大涨7.70%，Q2业绩超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1195849493","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195849493?lang=zh_cn&edition=full","pubTime":"2025-08-07 20:41","pubTimestamp":1754570504,"startTime":"0","endTime":"0","summary":"生物制药公司Mirum Pharmaceuticals, Inc.今日盘前大涨7.70%，主要受益于公司发布的强劲第二季度财报以及上调的全年业绩指引。根据公司公告，Mirum第二季度总营收达到1.28亿美元，表现优异。鉴于良好的商业表现，Mirum将2025年全年营收指引上调至4.9亿至5.1亿美元，进一步提振了投资者信心。除了财务业绩亮眼外，Mirum的药物研发管线也取得重要进展。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"gpt_icon":0},{"id":"1151055646","title":"异动解读 | Mirum Pharmaceuticals盘前大涨7.70%，第二季度业绩超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1151055646","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151055646?lang=zh_cn&edition=full","pubTime":"2025-08-07 20:41","pubTimestamp":1754570502,"startTime":"0","endTime":"0","summary":"周四盘前，Mirum Pharmaceuticals, Inc.股价大涨7.70%，主要受益于公司发布的强劲第二季度财务业绩报告以及上调的全年收入指引。根据公司公布的2025年第二季度财报，Mirum总营收达到1.28亿美元，其中全球净产品销售额为1.278亿美元。基于强劲的商业表现，Mirum将2025年全年营收指引上调至4.9亿至5.1亿美元。除了财务业绩外，Mirum还强调了其药物管线的重要进展。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"gpt_icon":1},{"id":"1111377490","title":"异动解读 | Mirum Pharmaceuticals盘后大涨9.20%，季度业绩远超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1111377490","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111377490?lang=zh_cn&edition=full","pubTime":"2025-08-07 05:58","pubTimestamp":1754517532,"startTime":"0","endTime":"0","summary":"生物制药公司Mirum Pharmaceuticals, Inc.今日盘后股价大涨9.20%，引发投资者关注。这一显著涨幅主要源于公司发布的最新季度财报数据大幅超出市场预期。根据公司公布的财报，截至6月30日的季度，Mirum Pharmaceuticals调整后每股亏损为12美分，远好于分析师平均预期的33美分亏损，也大幅改善了去年同期52美分的亏损。值得注意的是，华尔街分析师对Mirum Pharmaceuticals保持乐观态度。这表明市场对公司未来发展前景持积极看法，可能进一步支撑股价上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MIRM"],"gpt_icon":1},{"id":"2516480605","title":"Mirum Pharmaceuticals, Inc.2024财年实现净利润-87.94百万美元，同比增加46.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516480605","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516480605?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931269,"startTime":"0","endTime":"0","summary":"3月3日，Mirum Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-87.94百万美元，同比增加46.05%；其中营业收入为3.37亿美元，同比增加81.18%，每股基本收益为-1.85美元。从资产负债表来看，Mirum Pharmaceuticals, Inc.总负债4.45亿美元，其中短期债务1.71百万美元，资产负债比为1.51，流动比率为3.10。机构评级：截至2025年3月3日，当前有9家机构对Mirum Pharmaceuticals, Inc.目标价做出预测，其中目标均价为66.11美元，其中最低目标价为55.00美元，最高目标价为74.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000148abe4acd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000148abe4acd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MIRM"],"gpt_icon":0},{"id":"2514651385","title":"Mirum Pharmaceuticals, Inc.盘中异动 早盘大幅跳水7.68%报46.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514651385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514651385?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:32","pubTimestamp":1740666722,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时32分，Mirum Pharmaceuticals, Inc.股票出现波动，股价急速下跌7.68%。Mirum Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Mirum Pharmaceuticals, Inc.公司简介：Mirum Pharmaceuticals Inc 是一家生物制药公司，专注于识别、收购、开发和商业化用于使人衰弱的罕见疾病和孤儿疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272232029632b0e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272232029632b0e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1103386476","title":"Mirum Pharmaceuticals 2024年第四季度GAAP每股收益$(0.49)不及预期$(0.28)，销售额为9943万美元，超出预期9660.6万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103386476","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103386476?lang=zh_cn&edition=full","pubTime":"2025-02-27 06:10","pubTimestamp":1740607806,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals 报告季度每股亏损$，比分析师的预期$低75%。公司报告季度销售额为9943万美元，超出分析师预期的9660.6万美元，超出2.92%。这较去年同期的销售额6955.4万美元增长了42.95%。以上内容来自Benzinga Earnings专栏，原文如下：Mirum Pharmaceuticals  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 75 percent. This is a 25.76 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $99.430 million which beat the analyst consensus estimate of $96.606 million by 2.92 perce","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM"],"gpt_icon":0},{"id":"1113916189","title":"Mirum Pharmaceuticals第四季度销售额为9943万美元，超出预期的9660.6万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113916189","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113916189?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:18","pubTimestamp":1740604735,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals报告季度销售额为9943万美元，超出分析师一致预期的9660.6万美元，超出幅度为2.92%。这一数字较去年同期的销售额6955.4万美元增长了42.95%。以上内容来自Benzinga Earnings专栏，原文如下：Mirum Pharmaceuticals  reported quarterly sales of $99.430 million which beat the analyst consensus estimate of $96.606 million by 2.92 percent.  This is a 42.95 percent increase over sales of $69.554 million the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mirum Pharmaceuticals第四季度销售额为9943万美元，超出预期的9660.6万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirumpharma.com","stockEarnings":[{"period":"1week","weight":0.1845},{"period":"1month","weight":0.3769},{"period":"3month","weight":0.2213},{"period":"6month","weight":0.6951},{"period":"1year","weight":1.166},{"period":"ytd","weight":0.1331}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mirum Pharmaceuticals, Inc.于2018年5月2日在特拉华州注册成立。该公司是一家生物制药公司，专注于识别、收购、开发和商业化用于使人衰弱的罕见和孤儿疾病的新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.041296},{"month":2,"riseRate":0.833333,"avgChangeRate":0.061659},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.05038},{"month":4,"riseRate":0.5,"avgChangeRate":0.059141},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.035958},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097654},{"month":7,"riseRate":0.666667,"avgChangeRate":0.076249},{"month":8,"riseRate":0.714286,"avgChangeRate":0.107618},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.04362},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.10761},{"month":11,"riseRate":0.714286,"avgChangeRate":0.084664},{"month":12,"riseRate":0.571429,"avgChangeRate":0.315468}],"exchange":"NASDAQ","name":"Mirum Pharmaceuticals, Inc.","nameEN":"Mirum Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Mirum Pharmaceuticals, Inc.(MIRM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Mirum Pharmaceuticals, Inc.,MIRM,Mirum Pharmaceuticals, Inc.股票,Mirum Pharmaceuticals, Inc.股票老虎,Mirum Pharmaceuticals, Inc.股票老虎国际,Mirum Pharmaceuticals, Inc.行情,Mirum Pharmaceuticals, Inc.股票行情,Mirum Pharmaceuticals, Inc.股价,Mirum Pharmaceuticals, Inc.股市,Mirum Pharmaceuticals, Inc.股票价格,Mirum Pharmaceuticals, Inc.股票交易,Mirum Pharmaceuticals, Inc.股票购买,Mirum Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mirum Pharmaceuticals, Inc.(MIRM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Mirum Pharmaceuticals, Inc.(MIRM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}